Long MHC II peptides (approximately 30 amino acids) have gained considerable attention in the drug discovery process; these long MHC II peptides, once injected, are captured by DCs and presented to CD4 + cells, which are activated and selectively kill cancer cells [59, 60]. The gene discussed is CD4; the disease is cancer.